{
    "organizations": [],
    "uuid": "453e04ad77afed1672434e3e208d124644a89a3f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-diamyd-medical-diamyd-continues-to/brief-diamyd-medical-diamyd-continues-to-show-weaker-results-idUSFWN1R9015",
    "ord_in_thread": 0,
    "title": "BRIEF-Diamyd Medical: Diamyd Continues To Show Weaker Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - DIAMYD MEDICAL AB:\n* ‍DIAMYD® SUBCUTANEOUSLY CONTINUES TO SHOW WEAKER RESULTS THAN WHEN ADMINISTERED INTRALYMPHATICALLY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-27T14:28:00.000+03:00",
    "crawled": "2018-03-28T18:56:16.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "diamyd",
        "medical",
        "ab",
        "subcutaneously",
        "continues",
        "show",
        "weaker",
        "result",
        "administered",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}